Press Release Archive

 
05.06.2021 - Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games
*/ /*-->*/ /*-->*/

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc.

 
04.28.2021 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Charles Triano, Senior Vice President, Investor Relations, at the 7th Annual Truist Securities 2021 Life Sciences Summit on Wednesday, May 5, 2021 at 1:50 p.m. Eastern Daylight Time.

 
04.28.2021 - Pfizer Acquires Amplyx Pharmaceuticals
*/ /*-->*/ /*-->*/

Deal expands anti-infectives pipeline with addition of novel antifungal Phase 2 candidate, Fosmanogepix (APX001)

Opportunity to advance Pfizer’s expertise and deep heritage in infectious disease

 
04.22.2021 - Pfizer Declares Second-Quarter 2021 Dividend
*/ /*-->*/ /*-->*/

Board of Directors approves quarterly cash dividend of $0.39 per share

 
04.19.2021 - Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
  • European Union exercises option under previous agreement to order 100 million additional doses of COMIRNATY®, bringing total doses to 600 million for 27 EU member states
  • All doses expected to be delivered in 2021

NEW YORK and MAINZ, GERMANY, April 19, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY®, the companies’ COVID-19 vaccine, to the 27 European Union (EU) member states in 202

 
04.15.2021 - Pfizer Invites Shareholders to Attend Virtual-Only 2021 Annual Meeting of Shareholders on April 22
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that shareholders and the general public are invited to access its virtual-only 2021 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 22, 2021.

 
04.12.2021 - Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
  • SERENE is a Phase 3 single-arm, open-label study evaluating the contraceptive efficacy of investigational relugolix combination tablet in sexually active, healthy women ages 18-35 years
  • Contraceptive potential of relugolix combination tablet supported by prior Phase 1 study that demonstrated 100% ovulation inhibition
  • Data would support a potential indication of pregnancy prevention for women treated with relugolix combination tablet, if approved

BASEL, Switzerland and NEW YORK

 
04.02.2021 - Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Review Oncology Business on April 9, 2021
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of a presentation and conference call with investment analysts at 10 a.m. EDT on Friday, April 9, 2021.

 
04.01.2021 - Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
*/ /*-->*/ /*-->*/
  • Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second dose
  • Vaccine was 100% effective in preventing seve
 
03.31.2021 - Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
*/ /*-->*/ /*-->*/
  • In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier analysis, and was well tolerated
  • The companies plan to submit these d
 
03.26.2021 - EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union
  • New stability data show vaccine can be stored at -25°C to -15°C for a total of two weeks and support decentralized distribution plans for vaccination at general practitioners’ offices
  • Label update offers greater flexibility for distributing, storing and administering the vaccine within the European Union

New York and Mainz, Germany, March 26, 2021Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the European Medicines Agency (EMA) approved storag

 
03.25.2021 - Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
*/ /*-->*/ /*-->*/

NEW YORK & INDIANAPOLIS--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab.

 
03.25.2021 - Results from Pfizer’s Phase 3 Jade Compare Study of Abrocitinib in Moderate to Severe Atopic Dermatitis Published in New England Journal of Medicine

New York, March 24, 2021Pfizer Inc. (NYSE: PFE) today announced the publication of complete results from the JADE COMPARE study of investigational oral, once-daily, Janus kinase 1 (JAK1) inhibitor, abrocitinib in The New England Journal of Medicine (NEJM). The study evaluated the safety and efficacy of two doses of abrocitinib, 100mg and 200mg, versus placebo in adults with moderate to severe atopic dermatitis who were on background topical therapy.

 
03.25.2021 - Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer
*/ /*-->*/ /*-->*/

First large-scale comparative effectiveness analysis of a CDK 4/6 inhibitor plus letrozole evaluating progression-free and overall survival versus letrozole alone

 
03.24.2021 - Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
  • 78.4% of women who continued on relugolix combination therapy remained responders (menstrual blood loss < 80 mL) through Week 76 compared with 15.1% of women who discontinued treatment at Week 52 (p < 0.0001)
  • 69.8% of women who continued relugolix combination therapy remained responders through Week 104
  • 88.3% of women who discontinued treatment relapsed with heavy menstrual bleeding, on average 5.9 weeks after discontinuation
  • Myovant to host conference call and
 
03.23.2021 - Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2
*/ /*-->*/ /*-->*/
  • In-vitro studies conducted to date show that the clinical candidate PF-07321332 is a potent protease inhibitor with potent anti-viral activity against SARS-CoV-2
  • This is the first orally administered coronavirus-specific investigational p
 
03.23.2021 - Pfizer Invites Public to View and Listen to Webcast of Pfizer May 4 Conference Call with Analysts
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 4, 2021.

 
03.11.2021 - Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared
*/ /*-->*/ /*-->*/
  • Dramatically lower COVID-19 disease incidence rates observed in individuals fully vaccinated with the Pfizer-BioNTech vaccine, based on real-world data gathered by the Israel Ministry of Health  
  • Data suggest Pfizer-BioNTech vaccine prevents asymptomatic SARS-CoV-2

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.